Study Design. In vitro study using isolated human intervertebral disc (IVD) cells. Objective. To investigate the effects of prostaglandin (PG)E 1 and its orally available derivative limaprost on the regulation of nerve growth factor (NGF) expression and to compare their actions with other prostanoids using interleukin (IL)-1-stimulated human IVD cells. Summary of Background Data. We previously reported that a selective COX-2 inhibitor enhanced, whereas PGE 2 suppressed the induction of NGF by IL-1 in human IVD cells, and proposed that PGE 2 can suppress NGF expression by a negative feedback mechanism. Methods. Isolated human IVD cells were stimulated with IL-1 in the presence or absence of increasing concentrations of PGE 2 , PGE 1 , limaprost, PGI 2 , PGD 2 , or PGF 2a (10-10,000 nM). For some experiments, an E-series prostanoid receptor (EP)4 antagonist (L-161,982) was added prior to the stimulation. NGF expression was determined by real-time polymerase chain reaction and its protein level was quantified by enzyme-linked immunosorbent assay. Results. PGE 2 , PGE 1 , and limaprost inhibited the IL-1-mediated induction of NGF in a concentration-dependent manner, with IC 50 values of 9.9, 10.6, and 70.9 nM, respectively. PGI 2 also suppressed NGF expression but to a much less extent. PGD 2 , on the other hand, significantly enhanced NGF expression, whereas PGF 2a had no effect. Protein expression levels of NGF mirrored its mRNA levels. The suppression of NGF expression by PGE 2 and PGE 1 was partly reversed by L-161,982. Conclusion. PGE 1 and limaprost exhibited a novel pharmacological action that suppresses NGF expression in human IVD cells, and other prostanoids differentially regulated NGF expression. Limaprost has been used to treat patients with lumbar spinal stenosis in Japan and was proved to be effective in relieving symptoms. Our in vitro results may explain, in part, the mechanism of action of limaprost for low back pain.
L ow back pain (LBP) is a very common clinical condition 1 with an estimated lifetime prevalence of 70% to 85%. 2 This condition also increases socioeconomic burden, 3 accounting for approximately $100 billion in direct healthcare-associated costs in the United States in 2008. 4 Although the causes of LBP are diverse and more than 80% of patients with chronic LBP are classified as having nonspecific LBP, intervertebral disc (IVD) pathology has been considered a cause of LBP. 5 Innervation of the degenerated IVDs with sensory peripheral nerves was a unique feature observed in the painful IVDs of the patients. This disc pathology was found to be associated with the expression of nerve growth factor (NGF), [6] [7] [8] [9] which was originally identified as a trophic growth factor. The role of NGF in LBP was clarified after clinical trials revealed the effectiveness of neutralizing antibodies against NGF in pain relief. 10 An additional mechanism of NGF action in pain became clear, with a few studies indicating that NGF upregulates a calcitonin gene-related peptide, which sensitizes dorsal root ganglion neurons. 7, 11 However, the mechanism of action of drugs used for LBP treatment on NGF regulation largely remains unknown.
The proinflammatory cytokines interleukin (IL)-1, IL-6, and tumor necrosis factor a are considered to be involved in LBP development because they can induce a number of catabolic proteinases that cause IVD degeneration 12, 13 as well as produce pain-related molecules including PGE 2 and NGF in IVD cells. 9, [14] [15] [16] Indeed, neutralization of these cytokines with antibodies produced a reduction in the LBP pathology. 17, 18 Among these cytokines, IL-1 appeared to more strongly induce NGF expression in human IVD cells, 9, 14 suggesting that IL-1 plays important roles as a master-trigger for inducing IVD pathogenesis.
Nonsteroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase (COX)-2 inhibitors, are the most common first-choice conservative treatment for LBP. 19 Our previous in vitro study using cultured human IVD cells demonstrated that the induction of NGF by IL-1 was augmented by a selective COX-2 inhibitor (NS-398), and that PGE 2 can suppress NGF expression; hence, we suggested that the inhibition of PGE 2 by a selective COX-2 inhibitor may have limited efficacy for LBP. 20 However, these lines of evidence raised the possibility that PGE 1 , which is structurally similar to PGE 2 , may also have the ability to suppress NGF expression in human IVD cells. PGE 1 , similarly to PGE 2 , is known as a vasodilator that increases blood flow and inhibits platelet aggregation as mediated by the E-series of prostanoid receptors. 21, 22 EP4 activation has been shown to significantly increase blood vessel diameter and blood flow in a chronically compressed cauda equine model in the dog. 22 Limaprost is a derivative of PGE 1 developed in Japan. Modification in the PGE 1 structure has made limaprost resistant to inactivation in the lung and has allowed it to become available orally. 23 Clinically, limaprost has been used for lumbar canal stenosis (LCS) and has been proven to be effective in relieving symptoms, including leg pain, leg numbness, and accompanying gait disturbance with intermittent claudication. Interestingly, limaprost has also been reported to relieve LBP. 24, 25 In the present study, we investigated the effects of PGE 1 and limaprost on the regulation of NGF expression in IL-1-stimulated human IVD cells, and compared their actions with those of PGE 2 and other prostanoids, with the aim of exploring the possibility of developing PGE 1 -based therapies for the relief of LBP.
MATERIALS AND METHODS

Cell Culture
Human IVD cells were obtained from patients with LCS who received surgery in our hospital. The patients' age range was 42 to 85 years (mean 64.7 AE 11.1 yr, n ¼ 9). The patient details are provided in supplemental Table 1 , http://links. lww.com/BRS/B159. The Pfirrmann grading scale was used to score disc degeneration from grade 1 (nondegenerated disc) to grade 5 (severely degenerated disc). 26 This study was approved by the Ethics Review Committee of our institution. Written informed consent was obtained from all patients before the collection of specimens.
Immediately after surgery, human IVD cells were isolated as described previously. 20 Briefly, a mixture of nucleus pulposus and annulus fibrosus was minced and digested with 0.1% pronase (Sigma-Aldrich, St. Louis, MO) for 1 to 2 hours and then with 0.1% collagenase (Sigma-Aldrich) overnight with shaking. The cells were maintained in a monolayer in Dulbecco's Modified Eagle Medium (Life Technologies Corporation, Carlsbad, CA) containing 10% fetal bovine serum (Life Technologies Corporation), and 1% penicillin-streptomycin (Life Technologies Corporation). Cells up to the fourth passage were used for the following experiments.
Human IVD cells seeded as a monolayer on 12-well plates at a density of 5 Â 10 4 cells per well were grown until confluency. Confluent cells were serum-starved overnight and then stimulated with recombinant human IL-1b (10 ng/mL) (PeproTech, Rocky Hill, NJ) with or without PGE 1 , PGE 2 , limaprost, PGI 2 , PGD 2 , and PGF 2a (Cayman Chemical, Ann Arbor, MI) for 6 and 24 hours. For some experiments, cells were pretreated with an EP4 antagonist (L-161,982) (Cayman Chemical) for 1 hour and then stimulated with IL-1 in the presence or absence of PGE 1 or PGE 2 . For alginate culture, cells were resuspended in a 1.2% (w/v) solution (Sigma-Aldrich) at a density of 4 Â 10 6 cells/mL for more than 2 weeks to allow the cells to regain their native phenotype. 27 These cells were stimulated as descried above.
Microscopic Examination of Human IVD Cells
Human IVD cells cultured on 12-well plates were stimulated as descried above. After 24-hours culture, morphologic images of the cells were digitally captured using a Leica DM IL inverted contrast microscope equipped with a digital camera (Leica Microsystems, Wetzlar, Germany).
Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted using Total RNA Kit 1 (Omega Bio-Tek, Norcross, GA), and 300 ng of total RNA was reverse-transcribed using the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Quantitative real-time PCR was conducted using the Thermal Cycler Dice Real Time System (Takara, Shiga, Japan). Validated primer pairs for NGF and glyceradehyde-3-phosphate dehydrogenase (GAPDH) were purchased from Qiagen. NGF expression was estimated and expressed as the difference relative to the housekeeping gene GAPDH, using the delta-delta threshold cycles method of Sawaji et al 28 and Livak and Schmittgen. 29 
Enzyme-Linked Immunosorbent Assay (ELISA)
The amount of NGF was measured using the Duoset ELISA Development Kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. Optical density was determined at 450 nm using a microplate reader (Model 680, Bio-Rad Laboratories, Hercules, CA). Concentrations were calculated from a standard curve plot.
Statistical Analysis
Data were compared by one-way analysis of variance with the Dunnett multiple comparison tests using Prism 5 software (GraphPad Software, San Diego, CA). P-values less than 0.05 were considered to indicate a statistically significant difference between groups.
RESULTS
Suppression of NGF Expression by PGE 1 , PGE 2 , and Limaprost in IL-1-Stimulated Human IVD Cells
As IL-1 was highly expressed in degenerated IVD cells 30 and strongly upregulated NGF in human IVD cells, 31 IL-1 was used as an inducer of NGF in this study. We previously demonstrated that IL-1-induced NGF expression was enhanced when cells were pretreated with the selective COX-2 inhibitor NS-398 and that PGE 2 suppressed the NGF expression in these cells. These lines of evidence prompted us to examine whether PGE 1 and its derivative, limaprost, can similarly suppress NGF expression in human IVD cells.
As shown in Figure 1A , the induction of NGF expression by IL-1 was inhibited by PGE 1 in a similar concentration range to PGE 2 . PGE 1 and PGE 2 significantly inhibited NGF expression in a dose-dependent manner and significant inhibition was observed at as low as 10 nM for both PGs. Limaprost also showed inhibitory action, but this was milder than PGE 1 and PGE 2 . The IC 50 values of PGE 1 , PGE 2 , and limaprost on the induction of NGF by IL-1 were 9.9, 10.6, and 70.9 nM, respectively ( Figure 1B) .
As IVD cells cultured in a monolayer could change their phenotype, 27 we therefore performed similar experiments with the cells cultured in alginate beads to regain their original phenotype. There were no obvious differences between the two culture systems in the suppression of the IL-1-induced NGF expression by PGE 2 and PGE 1 (data not shown). Therefore, the following experiments were performed in a monolayer culture condition. Treatment of human IVD cells with PGE 1 or limaprost at 1 mM for 24 hours induced no changes in their morphology (Figure 2A-C) . IL-1 treatment changed the cell morphology from a spindle-like shape to a rounded shape ( Figure 2D) ; however, no obvious difference was observed when the cells were treated with IL-1 in the presence of PGE 1 and limaprost ( Figure 2E and F, respectively) .
Differential Regulation of NGF by Prostanoids in IL-1-Stimulated Human IVD Cells
Our previous research suggested that enhancement of the induction of NGF expression by NS-398 was due to inhibition of the suppressive action of PGE 2 on NGF expression. However, COX-2 also generates other prostanoids from arachidonic acid. Therefore, the effects of PGI 2 , PGD 2 , and PGF 2a on NGF expression were examined ( Figure 3 ). PGI 2 inhibited the induction of NGF by IL-1; however, the degree of suppression was much weaker than that of PGE 1 or PGE 2 . A significant difference was only detected at 10 mM PGI 2 . On the other hand, PGD 2 dose-dependently enhanced IL-1-induced NGF expression, which was significant at 10 mM PGD 2 whereas PGF 2a had no effect on NGF expression.
Regulation of NGF Production by Various Prostanoids in IL-1-Stimulated Human IVD Cells
Consistent with the above patterns of mRNA expression, PGE 2 and PGE 1 significantly suppressed NGF production; limaprost also suppressed NGF production but to a less extent than the former two PGs. PGI 2 showed a trend 
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ÃÃÃ indicate a significant difference from IL-1 alone (P < 0.05, P < 0.01, and P < 0.001, respectively). (B) Suppression of NGF expression by PGE 2 , PGE 1 , or limaprost was calculated by taking the relative amount of NGF in IL-1 treated cells as 100. The inhibitory dose-response curve was obtained and drawn using Prism software by the nonlinear regression method. The symbols indicate the mean AE SEM (n ¼ 4) of NGF after normalization to GAPDH. IVD indicates intervertebral disc; NGF, nerve growth factor. toward suppression of NGF production but it did not reach statistical significance, whereas PGD 2 significantly enhanced NGF production. PGF 2a had no effect on NGF production ( Figure 4 ).
An EP4 Antagonist Partially Reversed the Suppressive Action of PGE 1 and PGE 2 on NGF Expression in IL-1-Stimulated Human IVD Cells
Because we previously demonstrated that the suppression by PGE 2 of IL-1-stimulated NGF induction is mediated via EP2 and EP4, we tested whether the suppressive action of PGE 1 is also mediated by these receptors. The cells were pretreated with the EP4 antagonist L-161,982, and then stimulated with IL-1 with or without PGE 1 or PGE 2 . As shown in Figure 5 , the EP4 antagonist significantly enhanced the induction of NGF by IL-1, indicating that endogenous PGs released in response to IL-1 partially suppress NGF expression via the EP4. Suppression of NGF induction by PGE 1 and PGE 2 was also partially reversed by the EP4 antagonist, but the suppression levels did not reach those 
DISCUSSION
In this study, we found that NGF expression was suppressed by PGE 1 and limaprost. In addition, the suppression of NGF expression by PGE 1 was partially mediated by EP4. To the best of our knowledge, suppression of NGF expression by PGE 1 in human IVD cells has not been reported to date.
Because the association between the degree of innervation in IVDs and the expression of NGF has been shown in patients with severe LBP, NGF has been considered a target molecule for treating LBP. 7, 8, 32 Indeed, NGF neutralization with antibodies has been reported to be more effective than NSAIDs for relieving pain and improving function in patients with chronic LBP. 10, 33, 34 However, undesirable side effects of antibody therapy have emerged during clinical trials for the treatment of hip osteoarthritis, in which it increased the risk of rapidly progressive osteoarthritis and osteonecrosis. 33, 35 A molecule that negatively regulates NGF would, therefore, be a potential practical alternative to NGF antibodies.
There are few reports describing the regulation of NGF in human IVD cells by drugs that are used clinically. We reported that a steroid was a powerful suppressor of NGF expression, whereas a selective COX-2 inhibitor augmented NGF expression in IL-1-stimulated human IVD cells. 20 We also demonstrated that PGE 2 acts as a negative feedback molecule inhibiting the expression of NGF in these cells. 20 Our present study revealed that PGE 1 and its derivative limaprost also possess similar suppressive properties on NGF expression. The suppression of NGF by PGE 1 was partially mediated through EP4. The suppression was partial, presumably owing to the involvement of the EP2-mediated pathway, because our previous work demonstrated that the selective EP2 agonist butaprost suppressed the induction of NGF expression. Unfortunately, we were unable to test the involvement of the EP2 pathway in the present study owing to the lack of a commercially available selective EP2 antagonist. The suppressive action of PGE 1 was reported in an entrapment neuropathy model in diabetic rats, in which PGE 1 significantly suppressed NGF expression in the tibial nerve and reduced pain behavior, 36 suggesting that PGE 1 can attenuate NGF-related pain behavior in vivo.
The similar degrees of suppression of NGF expression by PGE 1 and PGE 2 can be explained by their affinity to the receptors. A study determining the Ki values of prostanoids to their receptors in Chinese hamster ovary cells overexpressing a series of receptors revealed that the Ki values of PGE 1 and PGE 2 to the EP2 and EP4 receptors were quite similar (Ki for EP2: 10 and 12 nM; and Ki for EP4: 1.9 and 2.1 nM, respectively). 37 Although those of limaprost have not been reported, limaprost retained its ability to suppress NGF expression.
COX-2 inhibitors inhibit the production of not only PGE 2 but also other prostanoids. We therefore investigated the effects of the other prostanoids on the regulation of NGF expression. PGI 2 suppressed NGF, whereas PGF 2a had no effect. Interestingly, PGD 2 enhanced the expression of NGF induced by IL-1 in human IVD cells. A similar effect of PGD 2 was reported in cultured mouse cortical astrocytes, 38 suggesting that PGD 2 potentially upregulates NGF expression. These results together with our previous work indicate that each prostanoid has a different effect on NGF expression and the enhancement of NGF expression by a selective COX-2 inhibitor may largely be due to inhibition of PGE 2 production. It should be noted, however, that the regulation of NGF by PGE 2 varies among the cell types used. For example, Toyomoto et al 38 reported that PGE 2 strongly stimulated the induction of NGF expression in mouse cortical astrocytes, whereas Pecchi et al 39 demonstrated that PGE 2 did not induce NGF expression in mouse articular chondrocytes.
Limaprost has been a conservative treatment of choice in Japan for LCS and was shown to have therapeutic benefits for relieving symptoms. 23 A randomized controlled study reported the more favorable effects of limaprost over etodolac. [40] [41] [42] Another trial also reported the more favorable effects of limaprost over etodolac in the improvement of not only leg pain and intermittent claudication but also LBP. 43 Furthermore, another study revealed that a combination of NSAIDs and limaprost was more effective in the management of LBP than monotherapy with either agent. 44 Considering our in vitro findings, the more favorable effects of combination therapy with the two drugs could be because COX-2 inhibitors suppress inflammatory pain by inhibiting PGE 2 , although this would increase NGF expression, whereas the combination therapy of COX-2 inhibitors with ÃÃÃ indicate a significant difference from IL-1 alone (P < 0.05 and P < 0.001, respectively). yy, P < 0.01.
limaprost would attenuate the enhancement of NGF expression, resulting in the relief of both inflammatory and NGF-associated pain.
This study has the following limitations. The concentrations of PGs that affected NGF regulation in vitro may not directly reflect concentrations in vivo. The mean maximum plasma concentration of limaprost, when a single 5-mg dose was administered to healthy adults, was reported to be 1.18 pg/mL, which is much lower than those used in our cell culture experiments. The other limitation is that being an in vitro study, we could not estimate the overall consequence of pain relieve. The classical action of PGs in pain is that PGs can directly activate or sensitize sensory neurons to other mediators, such as bradykin. 45, 46 On the other hand, several clinical studies have demonstrated that administration of PGs acts as a potential inhibitor of pain. [23] [24] [25] 42, 43 Although the exact mechanisms underlining the differential actions of PGs remain unknown, our results show the novel painrelieve action of PGs, that is, PGE 2 , PGE 1 , limaprost, and PGI 2 attenuate NGF induction in human IVD cells. Nevertheless, in vivo experiments are needed to fully clarify the overall efficacy of limaprost.
In conclusion, the results described in this study revealed a novel pharmacological action of PGE 1 and its derivative limaprost on the expression of NGF in human IVD cells and suggest the usefulness of PGE 1 for managing LBP.
Key Points
The objective of this study was to investigate the effects of PGE 1 and its derivative limaprost on the regulation of NGF, and to compare its effects with PGE 2 and other prostanoids in isolated human IVD cells. PGE 1 , limaprost, PGE 2 , and PGI 2 suppressed the induction of NGF expression by IL-1 in a dosedependent manner. PGD 2 enhanced the induction of NGF by IL-1, whereas PGF 2a had no effect. The suppression of NGF expression by PGE 1 and PGE 2 was partially mediated by the E-series prostanoid receptor 4. PGE 1 and limaprost may have a novel pharmacological effect in suppressing NGF expression, and can be considered a candidate conservative therapy for patients with low back pain.
